ERBB2 and breast carcinoma: Preliminary clinical studies from a consecutive series of breast cancer patients found that YAP/TAZ over-expression related to shorter disease-free survival, and a statistically obvious correlation between YAP/TAZ and HER2 positivity had also been proved (Bartucci et al., 2015).